scholarly journals Total Lymphocyte Count and World Health Organization Pediatric Clinical Stage as Markers to Assess Need to Initiate Antiretroviral Therapy Among Human Immunodeficiency Virus-Infected Children in Moshi, Northern Tanzania

2009 ◽  
Vol 28 (6) ◽  
pp. 493-497 ◽  
Author(s):  
Opemipo O. Johnson ◽  
Daniel K. Benjamin ◽  
Daniel K. Benjamin ◽  
Werner Schimana ◽  
L Gayani Tillekeratne ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Antiretroviral Therapy ◽  
World Health Organization ◽  
Lymphocyte Count ◽  
Clinical Stage ◽  
Total Lymphocyte Count ◽  
World Health ◽  
Northern Tanzania ◽  
Immunodeficiency Virus ◽  
Health Organization

scholarly journals Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study

2020 ◽  
Author(s):  
Anna Maria Geretti ◽  
Alexander J Stockdale ◽  
Sophie H Kelly ◽  
Muge Cevik ◽  
Simon Collins ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
World Health Organization ◽  
Cox Regression ◽  
World Health ◽  
Rank Test ◽  
Hiv Positive ◽  
Protein Levels ◽  
Increased Risk ◽  
Immunodeficiency Virus ◽  
Health Organization

Abstract Background Evidence is conflicting about how human immunodeficiency virus (HIV) modulates coronavirus disease 2019 (COVID-19). We compared the presentation characteristics and outcomes of adults with and without HIV who were hospitalized with COVID-19 at 207 centers across the United Kingdom and whose data were prospectively captured by the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) World Health Organization (WHO) Clinical Characterization Protocol (CCP) study. Methods We used Kaplan-Meier methods and Cox regression to describe the association between HIV status and day-28 mortality, after separate adjustment for sex, ethnicity, age, hospital acquisition of COVID-19 (definite hospital acquisition excluded), presentation date, 10 individual comorbidities, and disease severity at presentation (as defined by hypoxia or oxygen therapy). Results Among 47 592 patients, 122 (0.26%) had confirmed HIV infection, and 112/122 (91.8%) had a record of antiretroviral therapy. At presentation, HIV-positive people were younger (median 56 vs 74 years; P < .001) and had fewer comorbidities, more systemic symptoms and higher lymphocyte counts and C-reactive protein levels. The cumulative day-28 mortality was similar in the HIV-positive versus HIV-negative groups (26.7% vs. 32.1%; P = .16), but in those under 60 years of age HIV-positive status was associated with increased mortality (21.3% vs. 9.6%; P < .001 [log-rank test]). Mortality was higher among people with HIV after adjusting for age (adjusted hazard ratio [aHR] 1.47, 95% confidence interval [CI] 1.01–2.14; P = .05), and the association persisted after adjusting for the other variables (aHR 1.69; 95% CI 1.15–2.48; P = .008) and when restricting the analysis to people aged <60 years (aHR 2.87; 95% CI 1.70–4.84; P < .001). Conclusions HIV-positive status was associated with an increased risk of day-28 mortality among patients hospitalized for COVID-19.

scholarly journals Keberhasilan Pengobatan Terapi Antiretroviral

2017 ◽  
Vol 4 (1) ◽  
pp. 1
Author(s):  
Teguh H Karyadi
Keyword(s):  
Human Immunodeficiency Virus ◽  
Viral Load ◽  
World Health Organization ◽  
World Health ◽  
Immunodeficiency Virus ◽  
Health Organization ◽  
Hiv Aids

Pengobatan antiretroviral (ARV) kombinasi merupakan terapi terbaik bagi pasien terinfeksi Human Immunodeficiency Virus (HIV) hingga saat ini. Tujuan utama pemberian ARV adalah untuk menekan jumlah virus (viral load), sehingga akan meningkatkan status imun pasien HIV dan mengurangi kematian akibat infeksi oportunistik. Pada tahun 2015, menurut World Health Organization (WHO) antiretroviral sudah digunakan pada 46% pasien HIV di berbagai negara. Penggunaan ARV tersebut telah berhasil menurunkan angka kematian terkait HIV/AIDS dari 1,5 juta pada tahun 2010 menjadi 1,1 juta pada tahun 2015. Antiretroviral selain sebagai antivirus juga berguna untuk mencegah penularan HIV kepada pasangan seksual, maupun penularan HIV dari ibu ke anaknya. Hingga pada akhirnya diharapkan mengurangi jumlah kasus orang terinfeksi HIV baru di berbagai negara.

scholarly journals Profilaksis Pasca Pajanan terhadap Hepatitis B, Hepatitis C, dan Human Immunodeficiency Virus pada Petugas Kesehatan

2019 ◽  
Vol 6 (1) ◽  
pp. 1
Author(s):  
Alvina Widhani
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis C ◽  
Hepatitis B ◽  
World Health Organization ◽  
World Health ◽  
Immunodeficiency Virus ◽  
Health Organization

Petugas kesehatan berisiko terpajan dengan darah atau cairan tubuh lain yang dapat mengandung hepatitis B, hepatitis C, atau human immunodeficiency virus (HIV). World Health Organization (WHO) melaporkan 2,5% kasus HIV, 40% kasus hepatitis B, dan 40% kasus hepatitis C disebabkan karena penularan yang terkait dengan pekerjaan.

Pengalaman Pasien HIV/AIDS yang Menjalani Pengobatan Antiretroviral (ARV) di Yayasan Bina Muda Gemilang Balaraja Tangerang

2019 ◽  
Vol 8 (03) ◽  
pp. 130-135
Author(s):  
Zahrah Maulidia Septimar ◽  
Siti Robeatul Adawiyah
Keyword(s):  
Human Immunodeficiency Virus ◽  
Content Analysis ◽  
Viral Load ◽  
World Health Organization ◽  
Qualitative Content Analysis ◽  
World Health ◽  
Purposive Sampling ◽  
Immunodeficiency Virus ◽  
Health Organization ◽  
Hiv Aids

Pengobatan antiretroviral (ARV) kombinasi merupakan terapi terbaik bagi pasien terinfeksi Human Immunodeficiency Virus (HIV) hingga saat ini. Tujuan utama pemberian ARV adalah untuk menekan jumlah virus (viral load), sehingga akan meningkatkan status imun pasien HIV dan mengurangi kematian akibat infeksi oportunistik. Pada tahun 2015, menurut World Health Organization (WHO) antiretroviral sudah digunakan pada 46% pasien HIV di berbagai negara. Penggunaan ARV tersebut telah berhasil menurunkan angka kematian terkait HIV/AIDS dari 1,5 juta pada tahun 2010 menjadi 1,1 juta pada tahun 2015. Desain penelitian ini adalah kualitatif fenomenologi. Partisipan di tentukan dengan teknik purposive sampling berjumlah sepuluh orang dengan terdiri dari pasien yang positif HIV AIDS yang sedang menjalani pengobatan ARV.Tekhnik wawancara mendalam dilakukan menggunakan alat perekam dan panduan wawancara terstruktur, serta catatan lapangan.Analisa data menggunakan qualitative content analysis dengan pendekatan Collaizi. Tujuan penelitian ini di harapkan dapat menggali lebih dalam tentang pengalaman pasien HIV/AIDS yang menjalani pengobatan ARV. Dari hasil penelitian di temukan beberapa tema yang menjadi pembahasan tema yang di cantumkan berdasarkan apa yang terjadi pada pasien HIV/AIDS yang berkaitan dengan pengalaman konsumsi ARV. Yaitu pemahaman mengenai penyakit HIV/AIDS, mengalani ketidaknyamanan fisik, memahami ketidaknyamanan psikis, hambatan yang dialami selama pengobatan, dukungan selama menjalani pengobatan, harapan untuk mencapai kesembuhan dari penyakit. Diperlukan studi pendahuluan lebih lanjut untuk mengkaji secara mendalam tema yang telah teridentifikasi pada jumlah partisipan yang lebih banyak.

scholarly journals Reduction in Baseline CD4 Count Testing Following Human Immunodeficiency Virus “Treat All” Adoption in Uganda

2020 ◽  
Author(s):  
Esther Nasuuna ◽  
Mark W Tenforde ◽  
Alex Muganzi ◽  
Joseph N Jarvis ◽  
Yukari C Manabe ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
World Health Organization ◽  
Cd4 Count ◽  
World Health ◽  
Hiv Disease ◽  
Immunodeficiency Virus ◽  
Health Organization ◽  
Treat All ◽  
Advanced Hiv Disease ◽  
Cd4 Testing

Abstract Baseline CD4 testing rates declined from 73% to 21% between 2013 and 2018 with adoption of “Treat All” in Uganda. Advanced human immunodeficiency virus (HIV) disease (CD4 count < 200 cells/µL) remained common (24% of those tested in 2018, 83% of whom had World Health Organization stage I/II disease). Despite frequent presentation with advanced HIV disease, CD4 testing has declined dramatically.

Sign in / Sign up

Export Citation Format

Share Document